ZMZongchao Mo

Zongchao Mo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zongchao Mo has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Changhong Liang

    Department of Radiology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

    1 shared publication
  • Fangping Xu

    Department of Pathology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China

    1 shared publication
  • Haixia Shang

    Division of Life Science, Department of Chemical and Biological Engineering, and State Key Laboratory of Nervous System Disorders, The Hong Kong University of Science and Technology, Hong Kong, SAR, China

    1 shared publication
  • Haoyu Wang

    Division of Life Science, Department of Chemical and Biological Engineering, and State Key Laboratory of Nervous System Disorders, The Hong Kong University of Science and Technology, Hong Kong, SAR, China

    1 shared publication
  • Huan Lin

    Department of Radiology, Guangdong Provincial Peoples Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

    1 shared publication
  • Jiguang Wang

    The Hong Kong University of Science and Technology

    1 shared publication

Latest Publications

  • Open Access

    Multiomic integration reveals subtype-specific predictors of neoadjuvant treatment response in breast cancer

    by Zongchao Mo, Mei Yang, Zhihan Zhu, Minghao Wang, Haoyu Wang, Zhanye Zhang, Shanshan Lyu, Fangping Xu, Haixia Shang, Huan Lin, et al.

    Neoadjuvant therapy has been widely used in breast cancer, but treatment response varies among individuals. We conducted multiomic profiling on tumor samples from 149 Chinese patients with breast cancer across ER − HER2 + , ER + HER2 + , and ER − HER2 − subtypes, categorizing outcomes as pathologic complete response (pCR; n = 81) or residual disease (RD; n = 68). We identified distinct molecular features linked to pCR in each subtype: elevated cell proliferation in patients with ER − HER2 − pCR, higher CDKN2A methylation in patients with ER − HER2 − RD, increased KIT methylation in patients with ER − HER2 + RD, and MAP4K1 hypermethylation in patients with ER + HER2 + RD. These findings were subsequently validated in independent datasets. By integrating clinical and multiomic data, we developed MOPCR, a subtype-specific machine learning model that outperformed single-omic approaches in predicting treatment response. MOPCR demonstrated potential generalizability across cohorts and provided preliminary stratification of patient subgroups with higher pCR probability, offering valuable insights for precision cancer management.